GLP's ⏱ Half-life: Cagrilintide: ~7 days. Semaglutide: ~7 days. Both support once-weekly dosing. Phase 3

CagriSema

CagriSema (Cagrilintide + Semaglutide Combination)

Updated March 15, 2026

Evidence at a Glance

Regulatory statusPhase 3
Cagrilintide + semaglutide fixed-dose combo; NDA submitted to FDA Dec 2025, under review in 2026, not yet approved.
Human evidenceExtensive
Animal evidenceExtensive

CagriSema has completed large Phase 3 trials (REDEFINE 1 showed 22.7% mean weight loss over 68 weeks) and an FDA application is under review, but it is not yet approved.

What the research does not support

  • It is not yet FDA-approved; the New Drug Application was only submitted in December 2025 and remains under review.
  • Trial results, while strong, came in below some analyst expectations, it is not a guaranteed 25%-plus weight-loss agent.
  • It is not a cure for obesity, weight regain is expected if treatment stops, as with other GLP-1/amylin therapies.
Half-Life
Cagrilintide: ~7 days. Semaglutide: ~7 days. Both support once-weekly dosing.
Mol. Weight
Combination product

What is CagriSema?

CagriSema is a once-weekly combination therapy pairing semaglutide with cagrilintide, a novel long-acting amylin analog. By engaging both the GLP-1 and amylin appetite pathways simultaneously, it aims to achieve greater weight management efficacy than either component alone.

Research Applications

Phase 3 REDEFINE program for obesity, type 2 diabetes combination therapy, and comparative studies against semaglutide monotherapy.

Dosage Information (Research Use)

Fixed-dose combination administered once weekly subcutaneously. Titration follows semaglutide-style escalation. Investigational — research use only.

Reconstitution & Handling

Both components reconstituted together or separately depending on research protocol. Standard BAC water.

Half-Life & Pharmacokinetics

Cagrilintide: ~7 days. Semaglutide: ~7 days. Both support once-weekly dosing.

Reported Observations in Literature

GI effects consistent with GLP-1 and amylin agonism: nausea, vomiting, diarrhea. Phase 2 data suggests manageable with titration.

Key Research References

  • Frias JP, et al. “Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with semaglutide 2.4 mg.” Lancet. 2023

How CagriSema Works

CagriSema combines two distinct mechanisms: cagrilintide (a long-acting amylin analog that activates amylin and calcitonin receptors in the brainstem to reduce appetite and slow gastric emptying) with semaglutide (GLP-1 receptor agonist). The dual pathway approach targets complementary appetite centers — amylin works primarily through the area postrema and nucleus of the solitary tract, while GLP-1 acts on hypothalamic and brainstem GLP-1 receptors.

Research Findings

Phase 3 REDEFINE program ongoing. Phase 2 data showed approximately 15-17% weight loss at 32 weeks — competitive with tirzepatide on a shorter timeline. Represents Novo Nordisk's next-generation approach beyond semaglutide monotherapy. The amylin pathway adds a mechanistically distinct satiety signal.

Dosage & Administration

Fixed-dose combination administered once weekly subcutaneously. Titration follows semaglutide-style escalation. Investigational — research use only.

Safety & Side Effects

GI effects consistent with GLP-1 and amylin agonism: nausea, vomiting, diarrhea. Phase 2 data suggests manageable with titration.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence Cagrilintide (long-acting amylin analog) + Semaglutide (GLP-1 agonist)
Molecular Weight Combination product
Half-Life Cagrilintide: ~7 days. Semaglutide: ~7 days. Both support once-weekly dosing.
Available Sizes 5mg
Storage Lyophilized: -20°C. Reconstituted: 2-8°C, protect from light.

Key Research References

  • Frias JP, et al. "Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with semaglutide 2.4 mg." Lancet. 2023

Related Peptides

View all →
Semaglutide
GLP's
Long-acting GLP-1 receptor agonist extensively researched for metabolic regulation, glucose homeostasis, and body composition.
View Profile → Buy Now
Peptide YY
GLP's
Gut-derived satiety hormone that reduces appetite and regulates energy balance, with research implications for obesity treatment.
View Profile →
Retatrutide
GLP's
Investigational triple-hormone receptor agonist (GIP/GLP-1/glucagon) showing potent metabolic effects in early clinical trials.
View Profile → Buy Now